Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd., announced that it has finalized a settlement agreement with Amgen Inc., enabling the commercial launch of its Denosumab biosimilars in Europe and other international markets.
Under the terms of the agreement, Biocon Biologics will begin commercializing its Denosumab biosimilars—Vevzuo® and Evfraxy®—in Europe starting December 2, 2025. Additional terms of the settlement remain confidential.
Commenting on the development, Shreehas Tambe, CEO & Managing Director of Biocon Biologics, stated that the settlement marks an important advancement in the company’s efforts to expand global access to high-quality and affordable biologics. He noted that this agreement follows the company’s earlier settlement in the United States in October, further strengthening its presence in oncology and bone health therapeutic segments across key global markets.
Both Vevzuo and Evfraxy had received approval from the European Commission in July 2025, placing the biosimilars on firm regulatory footing ahead of commercialization. In the U.S. market, Biocon Biologics has already secured market entry dates for its Denosumab biosimilars Bosaya™ (denosumab-kyqq) and Aukelso™ (denosumab-kyqq).
